Table 1.
Characteristics of Current, Former, and Never Statin Users
| Current Statin Therapy (n=4182) | Discontinued Statin Therapy (n=464) | P Value vs Current | Declined Statin Therapy (n=153) | P Value vs Current | Never Offered (n=894) | P Value vs Current | |
|---|---|---|---|---|---|---|---|
| Demographics | |||||||
| Age, y | 68.0 (61.0–74.0) | 68.0 (61.0–75.0) | 0.56 | 67.0 (59.0–72.0) | 0.04 | 68.0 (60.0–72.0) | 0.02 |
| Sex (% male) | 2535 (60.6) | 197 (42.5) | <0.0001 | 64 (41.8) | <0.0001 | 437 (48.9) | <0.0001 |
| Race | |||||||
| White | 3581 (85.6) | 407 (87.7) | 0.56 | 128 (83.7) | 0.58 | 685 (76.6) | <0.0001 |
| Black | 504 (12.1) | 50 (10.8) | 23 (15.0) | 187 (20.9) | |||
| Asian | 86 (2.1) | 6 (1.3) | 2 (1.3) | 17 (1.9) | |||
| Other | 11 (0.3) | 1 (0.2) | 0 (0) | 5 (0.6) | |||
| Ethnicity: Hispanic | 419 (10.0) | 56 (11.2) | 0.43 | 30 (19.6) | 0.0001 | 125 (14.0) | 0.0005 |
| PALM practice type | |||||||
| Cardiology | 2102 (50.3) | 209 (45.0) | 0.18 | 56 (36.6) | 0.004 | 254 (28.4) | <0.0001 |
| Primary care/family practice/internal medicine | 1796 (43.0) | 217 (46.8) | 86 (56.2) | 570 (63.8) | |||
| Endocrinology | 146 (3.5) | 19 (4.1) | 8 (5.2) | 21 (2.4) | |||
| Other | 138 (3.3) | 19 (4.1) | 3 (2.0) | 49 (5.5) | |||
| Insurance status | |||||||
| Private | 2391 (57.3) | 256 (55.3) | 0.0002 | 103 (67.3) | 0.02 | 486 (54.4) | 0.0006 |
| Government | 1709 (41.0) | 186 (40.2) | 46 (30.1) | 374 (41.9) | |||
| Other/none | 72 (1.7) | 21 (4.5) | 4 (2.6) | 33 (3.7) | |||
| Education completed | |||||||
| At least some college | 2615 (63.6) | 306 (66.4) | 0.24 | 88 (58.3) | 0.18 | 502 (59.9) | 0.04 |
| Household income | |||||||
| ≤$35 000 | 957 (34.8) | 135 (40.8) | 0.07 | 35 (34.7) | 0.64 | 220 (41.4) | 0.02 |
| $35 000–$74 999 | 919 (33.4) | 112 (33.8) | 38 (37.6) | 162 (30.5) | |||
| $75 000–$99 999 | 319 (11.6) | 32 (9.7) | 8 (7.9) | 63 (11.8) | |||
| ≥$100 000 | 556 (20.2) | 52 (15.7) | 20 (19.8) | 87 (16.4) | |||
| Clinical characteristics | |||||||
| Any ASCVD | 2618 (62.6) | 222 (52.2) | <0.0001 | 58 (37.9) | <0.0001 | 266 (29.8) | <0.0001 |
| Prior MI | 801 (19.2) | 84 (18.1) | 0.58 | 9 (5.9) | <0.0001 | 35 (3.9) | <0.0001 |
| Prior stroke | 249 (6.0) | 39 (6.5) | 0.66 | 6 (3.9) | 0.29 | 29 (3.2) | 0.001 |
| Hypertension | 3518 (84.1) | 368 (79.3) | 0.01 | 115 (75.2) | 0.003 | 641 (71.7) | <0.0001 |
| Heart failure | 436 (10.5) | 59 (12.8) | 0.14 | 7 (4.6) | 0.02 | 55 (6.2) | <0.0001 |
| 10‐y risk (among primary prevention) | 14.5 (9.6–22.2) | 14.5 (9.6–21.7) | 0.60 | 14.4 (10.3–23.2) | 0.93 | 14.4 (9.7–21.0) | 0.81 |
| Lipids and therapy | |||||||
| Total cholesterol, mg/dL | 159.0 (137.0–185.0) | 215.0 (183.0–249.0) | <0.0001 | 205.0 (175.0–241.0) | <0.0001 | 194.0 (169.0–219.0) | <0.0001 |
| LDL‐C, mg/dL | 86.0 (68.0–107.0) | 134.0 (108.0–162.0) | <0.0001 | 125.0 (98.0–161.0) | <0.0001 | 117.0 (95.0–138.0) | <0.0001 |
| Currently on nonstatin lipid therapy | 1111 (26.9) | 132 (28.6) | 0.43 | 54 (35.8) | 0.02 | 198 (22.4) | 0.006 |
SI conversion factors: To convert cholesterol to mmol/L, multiply values by 0.0259. Data shown are median (interquartile range) or n (%). ASCVD indicates atherosclerotic cardiovascular disease; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PALM, Patient and Provider Assessment of Lipid Management.